Welcome to the latest issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter – download it here [1]. As the programme enters into its second year, we are pleased to see the first patients recruited into Work-strand 2 Bronchoscopy Study.
Recruitment is our focus this year across the five active studies: Work-strand 1 (Adherence, INCA-SUN and Biomarker Stratification Study), Work-strand 2 Bronchoscopy Study and Work-strand 3 SoMOSA. In this edition we’ll share updates on the programme as well as some more in-depth information on selected work-strands.
RASP-UK underwent its second progress review by the MRC on 18 Nov 16. There was a lively discussion with the group about recruitment, challenges faced with the new HRA approval process for clinical trials in England, and the importance of patient public engagement in clinical trials. The group were encouraged by the recruitment progress to date but wanted to emphasise the importance of delivering each of the studies within the programme. It was agreed that the T2-Low space still requires work to fully understand this population. The group noted that Industry is now taking non-adherence more seriously, and this is likely to be transformative in the next 3 – 4 years. In conclusion, the group agreed that the consortium is progressing well and that we are on target to deliver the programme.
We’d like to welcome GlaxoSmithKline to the consortium. GSK signed up to join the programme in late Dec 2016 and plan to support an adherence intervention study building on some of the learning from RASP-UK.
The second RASP-UK General Assembly Meeting was held on 6 Dec 2016. It was a great opportunity for the partners to meet and share the achievements from 2016, as well as looking forward to the challenges ahead for delivery of the programme. We had updates on all the work-strands as well as a look ahead to future research which aims to build on the learning’s from RASP-UK.
The RASP-UK Trial Steering Committee (TSC) met again on 02 March 17 to review safety in workstrands 1, 2 and 3. There were no safety concerns however the committee echoed the feedback from the MRC that recruitment remains the primary focus for the studies in 2017. They congratulated the team on their progress to date and agreed that the next review should take place in September 2017.
The newsletter reminds everyone that the RASP-UK website holds copies of all relevant study documents that can be accessed via the consortium website [2].
References
Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) approval for their live attenuated.
I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter
Advisory board meetings are often used to address perceived knowledge gaps and build consensus.
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
